Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Aviptadil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 9/20 | 0.84 |
| ▸ | VIPR2 | P41587 | 10/20 | 0.81 |
| ▸ | GLP1R | P43220 | 5/20 | 0.73 |
| ▸ | CCKBR | P32239 | 1/20 | 0.73 |
| ▸ | ECE1 | P42892 | 1/20 | 0.69 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.69 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382043 | 0.95 | GLP1R (0.80) | VIPR1VIPR2GLP1RCCKBRECE1 | |
| SCHEMBL29382033 | 0.94 | GLP1R (0.78) | VIPR1VIPR2GLP1RCCKBRECE1 | |
| Vasoactive Intestinal Peptide SCHEMBL30752406 | 0.93 | VIPR1 (0.73) | VIPR1VIPR2GLP1RCCKBRECE1 | |
| Vasoactive Intestinal Peptide SCHEMBL3041046 | 0.92 | VIPR1 (0.72) | VIPR1VIPR2GLP1RCCKBR | |
| Aviptadil SCHEMBL30969141 | 0.92 | VIPR1 (0.72) | VIPR1VIPR2GLP1RCCKBR | |
| SCHEMBL29496440 | 0.92 | VIPR1 (0.71) | VIPR1VIPR2GLP1RCCKBRPTH1R | |
| Oxyntomodulin SCHEMBL29349603 | 0.92 | GLP1R (0.84) | VIPR1GLP1RCCKBRECE1MUS81 | |
| SCHEMBL30542042 | 0.91 | VIPR1 (0.70) | VIPR1VIPR2GLP1RCCKBRECE1 | |
| Spinigerin SCHEMBL29593748 | 0.91 | VIPR2 (0.70) | VIPR1VIPR2GLP1RCCKBRECE1 | |
| SCHEMBL29403715 | 0.90 | VIPR1 (0.72) | VIPR1VIPR2GLP1RCCKBRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 702 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4731243-A2 | IN SITU THERAPEUTIC PRODUCTION: METHODS AND COMPOSITIONS | William Marsh Rice University (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4611721-A1 | STABLE AVIPTADIL FORMULATIONS | Relief Therapeutics International SA (CH) | 2025-09-10 | — | — | EP | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20220323546-A1 | RECOMBINANT INTERFERON | ALTUM PHARMACEUTICALS INC. (CA) | 2022-10-13 | — | — | US | claimed |
| CN-115066254-A | Human anti-inflammatory peptides for inhalation treatment of inflammatory lung diseases | 阿德维塔生命科学有限责任公司 | 2022-09-16 | — | — | CN | claimed |
| US-20220175889-A1 | NEW DOSAGE REGIMEN FOR INHALED VASOACTIVE INTESTINAL POLYPEPTIDE | CENTURION ILAÇ SANAYI VE TICARET ANONIM SIRKETI (TR) | 2022-06-09 | — | — | US | claimed |
| WO-2022119535-A1 | NEW DOSAGE REGIMEN FOR INHALED VASOACTIVE INTESTINAL POLYPEPTIDE | CENTURION ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2022-06-09 | — | — | WO | claimed |
| WO-2022106984-A2 | SMALL MOLECULE INHIBITORS OF SARS-COV2 MAIN PROTEASE | NANTCELL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220133630-A1 | PREPARATION METHOD OF SUSTAINED-RELEASE MICROPARTICLES | AC PHARMACEUTICALS CO., LTD. (CN) | 2022-05-05 | — | — | US | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| WO-2022081406-A1 | PHARMACEUTICALS FOR COVID19 TREATMENT | IMMUNITYBIO, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022076903-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022028917-A2 | METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT | SCIOMICS GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | VIPR1 3306/4885VIPR2 2742/4885GLP1R 4/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | VIPR1 874/4885VIPR2 685/4885GLP1R 130/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | VIPR1 813/4885VIPR2 565/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.